Akari’s robust PK/PD model simulated 10,000 virtual patients informing U.S. FDA MIDD interactions that helped confirm PK/PD model suitability & doses selected for Phase 3 Part A #nomacopan study in severe pediatric HSCT-TMA, currently underway. #TMA #FDA
